SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Powell Jonathan)
 

Sökning: WFRF:(Powell Jonathan) > The development of ...

The development of in vitro culture methods to characterize primary T-cell responses to drugs.

Faulkner, Lee (författare)
Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, U.K
Martinsson, Klara (författare)
Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, U.K
Santoyo-Castelazo, Anahi (författare)
Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, U.K
visa fler...
Cederbrant, Karin (författare)
Molecular Toxicology, Global Safety Assessment, AstraZeneca R&D, S-151 85 Södertälje, Sweden
Schuppe-Koistinen, Ina (författare)
Molecular Toxicology, Global Safety Assessment, AstraZeneca R&D, S-151 85 Södertälje, Sweden
Powell, Helen (författare)
Molecular Toxicology, Global Safety Assessment, AstraZeneca R&D, Alderley Park, Macclesfield SK10 4TG, U.K
Tugwood, Jonathan (författare)
Molecular Toxicology, Global Safety Assessment, AstraZeneca R&D, Alderley Park, Macclesfield SK10 4TG, U.K
Naisbitt, Dean J (författare)
Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, U.K
Park, B Kevin (författare)
Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, U.K
visa färre...
Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3GE, UK Molecular Toxicology, Global Safety Assessment, AstraZeneca R&D, S-151 85 Södertälje, Sweden (creator_code:org_t)
2012-02-13
2012
Engelska.
Ingår i: Toxicological Sciences. - : Oxford University Press. - 1096-6080 .- 1096-0929. ; 127:1, s. 150-8
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Adverse drug reactions represent a major stumbling block to drug development and those with an immune etiology are the most difficult to predict. We have developed an in vitro T-cell priming culture method using peripheral blood from healthy volunteers to assess the allergenic potential of drugs. The drug metabolite nitroso sulfamethoxazole (SMX-NO) was used as a model drug allergen to establish optimum assay conditions. Naive T cells were cocultured with monocyte-derived dendritic cells at a ratio of 25:1 in the presence of the drug for a period of 8 days, to expand the number of drug-responsive T cells. The T cells were then incubated with fresh dendritic cells, and drug and their antigen responsiveness analyzed using readouts for proliferation, cytokine secretion, and cell phenotype. All five volunteers showed dose-dependent proliferation as measured by 5-(and 6)-carboxyfluorescein diacetate succinimidyl ester content and by (3)H-thymidine uptake. CD4 T cells that had divided in the presence of SMX-NO had changed from a naive phenotype (CD45RA+) to a memory phenotype (CD45RO+). These memory T cells expressed the chemokine receptors CCR2, CCR4, and CXCR3 suggesting a mixture of T(H)1 and T(H)2 cells in the responding population, with a propensity for homing to the skin. Drug stimulation was also associated with the secretion of a mixture of T(H)1 cytokines (interferon γ) and T(H)2 cytokines (interleukin [IL]-5 and IL-13) as detected by ELISpot. We are currently developing this approach to investigate the allergenic potential of other drugs, including those where an association between specific human leucocyte antigen alleles and susceptibility to an immunological reaction has been established.

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy